Singular Genomics Systems

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Singular Genomics Systems reports Q1 loss but anticipates G4X launch

Singular Genomics Systems faces financial challenges with negative gross profit and a net loss in Q1 2024, but the G4X spatial sequencer holds promise for addressing spatial sequencing limitations. The company is strategically positioning itself for the commercial launch of G4X in 2025.

Singular Genomics reports revenue growth amidst operational challenges and opportunities

Singular Genomics Systems showed mixed financial performance in Q2 2024, with revenue growth but negative gross profit.
The company's focus on innovation, cost management, and product development positions it for future growth opportunities.
Opportunities in the G4X technology and services program offer potential for revenue expansion and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer, David Barker and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase

BioVie Inc

Galera Therapeutics

iSpecimen

23andMe

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good day, everyone, and welcome to the Singular Genomics Systems, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

Singular Genomics Systems, Inc. (OMIC) Q2 2023 Earnings Call Transcript

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2023.

Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the UBS MedTech, Tools and Genomics Summit in Dana Point, California.

Singular Genomics Announces Participation in the UBS MedTech, Tools and Genomics Summit

SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder and CEO Dalen Meeter - CFO Conference Call Participants Tom Stevens - TD Cowen John Sourbeer - UBS Michael Ryskin - Bank of America Operator Greetings. Welcome to the Singular Genomics Systems, Incorporated First Quarter 2023 Earnings Conference Call.

Singular Genomics Systems, Inc. (OMIC) Q1 2023 Earnings Call Transcript

Similar Genomics Systems (OMIC) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.

Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2023.

Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial Results

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Singular Genomics to Report First Quarter 2023 Financial Results on May 9, 2023

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Drew Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Matt Sykes - Goldman Sachs Daniel Brennan - Cowen & Co. Operator Greetings, and welcome to the Singular Genomics Systems, Incorporated Fourth Quarter 2022 Earnings Conference Call.[Operator Instructions] Please note, this conference is being recorded.

Singular Genomics Systems, Inc. (OMIC) Q4 2022 Earnings Call Transcript

Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 21.62% and 27.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2022.

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at Cowen's 43rd Annual Health Care Conference in Boston, Massachusetts.

Singular Genomics to Present at Cowen's 43rd Annual Health Care Conference

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, March 2, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Singular Genomics to Report Fourth Quarter 2022 Financial Results on March 2, 2023

Singular Genomics Systems is a unique opportunity to invest in a commercially-viable startup at the forefront of a rapidly expanding field. The company has adequate funding to maintain its current level of commercialization and sales activity for a few years.

Singular Genomics: Betting On Expanding Genomics Systems Market

The datasets are the latest to validate the performance and plug-and-play capability of the G4 across multiple applications The datasets are the latest to validate the performance and plug-and-play capability of the G4 across multiple applications

Singular Genomics Showcases New G4 Sequencing Platform Data with 11 Industry-Leading Genomics Partners at AGBT

- New next-generation sequencing kit maximizes throughput and decreases the cost for single cell experiments -

Singular Genomics Launches Max Read™ Kits for Single Cell Sequencing on the G4 at AGBT

– Demonstrates compatibility of the G4 Sequencing Platform with 10x Genomics Single Cell Applications –

Singular Genomics Joins the 10x Genomics Compatible Partner Program

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited fourth quarter 2022 revenue.

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue

SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Bruce Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tom Stevens - Cowen John Sourbeer - UBS Operator Good day, ladies and gentlemen and welcome to the Singular Genomics Systems, Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor, Investor Relations for Singular Genomics.

Singular Genomics Systems, Inc. (OMIC) Q3 2022 Earnings Call Transcript

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended September 30, 2022.

Singular Genomics Reports Recent Highlights and Third Quarter 2022 Financial Results

SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Singular Genomics to Report Third Quarter 2022 Financial Results on November 7, 2022

Presentation now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022 Presentation now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022

News for Singular Genomics Systems Stock (OMIC)